Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia (AML)

Inhibition of cholesterol synthesis and uptake sensitizes acute myeloid leukemia (AML) blasts to chemotherapy. A Phase 2 study of high dose pravastatin given in combination with idarubicin and cytarabine demonstrated an impressive response rate [75% complete remission (CR), CR with incomplete count...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Res
Main Authors: Advani, Anjali S., Li, Hongli, Michaelis, Laura C., Medeiros, Bruno C., Liedtke, Michaela, List, Alan F., O’Dwyer, Kristen, Othus, Megan, Erba, Harry P., Appelbaum, Frederick R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6574123/
https://ncbi.nlm.nih.gov/pubmed/29407182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2018.01.021
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados